Valeant: Another Fine Mess

Michael Pearson's "Leap Day" return to Valeant Pharmaceuticals International Inc. was supposed to be a victory for the CEO and his firm after he'd spent the past few months on sick leave recovering from a severe bout of pneumonia.

Michael Pearson's "Leap Day" return to Valeant Pharmaceuticals International Inc. was supposed to be a victory for the CEO and his firm after he'd spent the past few months on sick leave recovering from a severe bout of pneumonia.

More from Dermatological

Almirall Looks To Dominate Across Derma Spectrum

 
• By 

CEO Carlos Gallardo tells Scrip the Barcelona-based group has laid the foundations to advance four promising assets that have considerable potential for a variety of dermatological diseases.

Incyte’s Povorcitinib Looks Approvable In HS, But How Competitive?

 
• By 

Incyte’s JAK1 inhibitor meets the primary endpoint in two Phase III hidradenitis suppurativa trials, but the drug may not be able to supplant established biologic therapies.

J&J Dreams Of ICONIC Status For Icotrokinra

 
• By 

Having bested BMS's oral psoriasis drug Sotyktu, the closely watched once-daily IL-23 blocker is going head-to-head with J&J's own autoimmune mega-blockbuster Stelara.

Novartis Joins MRGPRX2 Race Through $800m+ Kyorin Deal

 
• By 

Swiss major gains global rights to preclinical asset as it joins race for MRGPRX2 antagonists in urticaria, where some same-class rivals are already in Phase II.

More from Therapy Areas

Vertex Ends One Type 1 Diabetes Cell Therapy, Shifts Focus To Another

 
• By 

Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.

Corcept’s Relacorilant Shows Benefit In Ovarian Cancer, Expanding Pipeline Opportunity

 

A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.

AstraZeneca Oral PCSK9 Prospects Pumped After Phase IIb Win

 
• By 

The UK giant is forecasting peak sales of $5bn plus